Biochemistry, Genetics and Molecular Biology
Epigenetics
100%
Cytogenetics
100%
Cell Cycle
100%
RNA
100%
Somatic Mutation
100%
Chromosome 9
100%
Dysplasia
100%
Gene Promoter
100%
Chromatin Remodeling
100%
Next Generation Sequencing
100%
Molecular Biology
100%
Fibroblast Growth Factor Receptor 3
100%
PI3K/AKT/mTOR Pathway
100%
Cancer Genomics
100%
Genomic Instability
100%
Keyphrases
Bladder Cancer
100%
Cancer Genomics
100%
Muscle-invasive Bladder Cancer
83%
Non-muscle Invasive Bladder Cancer (NMIBC)
66%
Urothelial Carcinoma
33%
Tumor Protein p53 (TP53)
33%
Molecular Alterations
33%
Epigenetic Modification
16%
Solid Tumors
16%
Quality of Life
16%
Cancer Biology
16%
Better Prognosis
16%
Genomic Instability
16%
Tumor
16%
Multiple Signaling Pathways
16%
Somatic mutation
16%
Natural History
16%
Early Events
16%
Worse Prognosis
16%
Chromosome 9
16%
Papillary
16%
Heterogeneous Disease
16%
Stage at Presentation
16%
Advanced Stage
16%
Dysplasia
16%
Gene Promoter
16%
Cancer Pathogenesis
16%
Natural Response
16%
Fibroblast Growth Factor Receptor 3 (FGFR3)
16%
Pathway Genes
16%
Systemic Treatment
16%
Cell Cycle Regulators
16%
HTERT Gene
16%
Inpatient Outcomes
16%
Next-generation Sequencing
16%
Patient Quality
16%
Histological Study
16%
Chromatin Remodeling Genes
16%
Cytogenetic Study
16%
KMT2D
16%
KDM6A
16%
Tailored Treatment
16%
PI3K-AKT-mTOR Pathway
16%
Two-pathway Model
16%
Cancer Heterogeneity
16%
Epithelial Hyperplasia
16%
Molecular Biology Techniques
16%
RNA Expression Profiling
16%
Papillary Histology
16%
Medicine and Dentistry
Bladder Cancer
100%
Muscle Invasive Bladder Cancer
83%
Non Muscle Invasive Bladder Cancer
66%
Transitional Cell Carcinoma
33%
Diseases
33%
Solid Malignant Neoplasm
16%
Quality of Life
16%
Cell Cycle
16%
Division
16%
Chromosome 9
16%
Dysplasia
16%
Systemic Therapy
16%
Next Generation Sequencing
16%
Fibroblast Growth Factor Receptor 3
16%
Somatic Mutation
16%
Cancer Pathobiology
16%
Cell Signaling Pathway
16%
Gene Promoter
16%
PI3K/AKT/mTOR Pathway
16%
Chromatin Remodeling
16%
Tumor
16%
Epithelium Hyperplasia
16%
Bladder Muscle
16%
Genomic Instability
16%